セキ　マサフミ   SEK Masafumi   関　雅文    所属   埼玉医科大学  医学部 国際医療センター　感染症科・感染制御科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S-aureus in a model of haematogenous pulmonary infection
掲載誌名	正式名：INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS ISSNコード：09248579
出版社	ELSEVIER SCIENCE BV
巻・号・頁	32(5),401-404頁
著者・共著者	Katsunori Yanagihara,Yuriko Ohnishi,Yoshitomo Morinaga,Shigeki Nakamura,Shintaro Kurihara,Masafumi Seki,Koichi Izumikawa,Hiroshi Kakeya,Yoshihiro Yamamoto,Yasuaki Yamada,Shigeru Kohno,Shimeru Kamihira
発行年月	2008/11
概要	ME1036, a novel parenteral carbapenem, was developed for the treatment of meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. aureus (VISA). A model of haematogenous pulmonary infection was induced in mice by tail vein injection of MRSA strain NUMR101 or VISA Mu50 enmeshed in agar beads. After 24 h of infection, mice were treated twice daily for 7 days with 200 mg/kg/day vancomycin (VCM) or ME1036. Mice infected with VISA were also pre-treated with cyclophosphamide to induce an immunocompromised state. The number of viable bacteria in the lungs was counted 12 h after the final drug treatment. VCM decreased the number of viable MRSA in the lungs in comparison with the control, although the difference was not significant (mean +/- standarderror of the mean log(10) colony-forming units (CFU)/lung = 6.876 +/- 0.54 vs. 8.25 +/- 0.41, respectively). In contrast, treatment with ME1036 resulted in a significant decrease in the number of viable MRSA (log(10) CFU/lung = 2.69 +/- 0.44 (n = 6); P<0.0001) compared with both the VCM-treated and control mice. In the VISA-infected mice, ME1036 significantly reduced the number of viable bacteria compared with VCM and
DOI	10.1016/j.ijantimicag.2008.04.030
PMID	18715761